{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:04:37Z","timestamp":1792789477752,"version":"4.5.0"},"reference-count":86,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-028"],"award-info":[{"award-number":["2021-I2M-1-028"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists may have potential benefits for mental illnesses. However, their exact effects remain unclear. This study investigated the causal relationship between glucagon-like peptide-1 receptor agonist (GLP1RA) and the risk of 10 common mental illnesses, including attention deficit and hyperactivity disorder, anorexia nervosa, anxiety disorder, autism spectrum disorder, bipolar disorder, major depressive disorder, post-traumatic stress disorder, schizophrenia, cannabis use disorder, and alcohol use disorder. We selected GLP1RA as the exposure and conducted a Mendelian randomization (MR) analysis. The cis-eQTLs of the drug target gene GLP1R, provided by eQTLGen, were used to simulate the pharmacological effects of GLP1RA. Type 2 diabetes and BMI were included as positive controls. Using data from both the Psychiatric Genomic Consortium and FinnGen, we conducted separate MR analyses for the same disease across these two independent databases. Meta-analysis was used to pool the results. We found genetic evidence suggesting a causal relationship between GLP1RA and a reduced risk of schizophrenia [OR (95% CI) = 0.84 (0.71\u20130.98), I2 = 0.0%, common effects model]. Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI. However, the findings of this study provide insufficient evidence to support a causal relationship between GLP1RA and other mental illnesses. Sensitivity analyses did not reveal any potential bias due to horizontal pleiotropy or heterogeneity in the above results (p &gt; 0.05). This study suggests that genetically proxied activation of glucagon-like peptide-1 receptor is associated with a lower risk of schizophrenia. GLP1R is implicated in schizophrenia pathogenesis, and its agonists may exert potential benefits through weight management. Our study provides useful information for understanding the neuropsychiatric effects of GLP1RA, which may contribute to refining future research designs and guiding clinical management. Moreover, our findings could have significant implications for overweight individuals at high risk of schizophrenia when selecting weight-loss medications. Future research should further investigate the potential mechanisms underlying the relationship between GLP1RA and schizophrenia.<\/jats:p>","DOI":"10.3390\/ijms26062741","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:02:31Z","timestamp":1742295751000},"page":"2741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3966-6844","authenticated-orcid":false,"given":"Longgang","family":"Xiang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7480-7881","authenticated-orcid":false,"given":"Ying","family":"Peng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40263-015-0301-8","article-title":"Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer\u2019s Disease and Other Neurodegenerative Diseases","volume":"29","author":"Calsolaro","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pcad.2021.09.007","article-title":"Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States","volume":"68","author":"Aggarwal","year":"2021","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(19)30934-1","article-title":"New WHO prevalence estimates of mental disorders in conflict settings: A systematic review and meta-analysis","volume":"394","author":"Charlson","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ije\/dyu038","article-title":"The global prevalence of common mental disorders: A systematic review and meta-analysis 1980\u20132013","volume":"43","author":"Steel","year":"2014","journal-title":"Int. J. Epidemiol."},{"key":"ref_8","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1789\u20131858."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2215-0366(15)00505-2","article-title":"Estimating the true global burden of mental illness","volume":"3","author":"Vigo","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tsai, W.H., Sung, F.C., Chiu, L.T., Shih, Y.H., Tsai, M.C., and Wu, S.I. (2022). Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: A nationwide, population-based cohort study. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.765446"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., and Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721135"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Reich, N., and H\u00f6lscher, C. (2022). The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review. Front. Neurosci., 16.","DOI":"10.3389\/fnins.2022.970925"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kim, Y.K., Kim, O.Y., and Song, J. (2020). Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01270"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41366-020-0535-5","article-title":"Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: A randomized, controlled study","volume":"44","author":"Vadini","year":"2020","journal-title":"Int. J. Obes."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xie, Y., Choi, T., and Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP1R agonists. Nat. Med., in press.","DOI":"10.1038\/s41591-024-03412-w"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2009.812","article-title":"Mendelian randomization: Nature\u2019s randomized trial in the post-genome era","volume":"301","author":"Thanassoulis","year":"2009","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2019Mendelian randomization\u2019: Can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int. J. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/ije\/dyx207","article-title":"Mendelian randomization: A novel approach for the prediction of adverse drug events and drug repurposing opportunities","volume":"46","author":"Walker","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian Randomization Study of ACLY and Cardiovascular Disease","volume":"380","author":"Ference","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.109.865444","article-title":"Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms","volume":"121","author":"Sofat","year":"2010","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hingorani, A.D., Kuan, V., Finan, C., Kruger, F.A., Gaulton, A., Chopade, S., Sofat, R., MacAllister, R.J., Overington, J.P., and Hemingway, H. (2019). Improving the odds of drug development success through human genomics: Modelling study. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-54849-w"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00125-023-05925-4","article-title":"Genetically proxied glucose-lowering drug target perturbation and risk of cancer: A Mendelian randomisation analysis","volume":"66","author":"Yarmolinsky","year":"2023","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e650","DOI":"10.1212\/WNL.0000000000200771","article-title":"Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study","volume":"99","author":"Tang","year":"2022","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1186\/s12967-023-04565-x","article-title":"Genetically proxied antidiabetic drugs targets and stroke risk","volume":"21","author":"Zhu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fu, K., Si, S., Jin, X., Zhang, Y., Duong, V., Cai, Q., Li, G., Oo, W.M., Zheng, X., and Boer, C.G. (2024). Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis. EBioMedicine, 107.","DOI":"10.1016\/j.ebiom.2024.105285"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1176\/appi.ajp.159.8.1395","article-title":"Cognitive correlates of job tenure among patients with severe mental illness","volume":"159","author":"Gold","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2045125318781475","article-title":"The acute efficacy of antipsychotics in schizophrenia: A review of recent meta-analyses","volume":"8","author":"Haddad","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_32","first-page":"2449","article-title":"Liraglutide improves cognitive impairment via the AMPK and PI3K\/Akt signaling pathways in type 2 diabetic rats","volume":"18","author":"Yang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neures.2009.01.013","article-title":"The influences of juvenile diabetes on memory and hippocampal plasticity in rats: Improving effects of glucagon-like peptide-1","volume":"64","author":"Iwai","year":"2009","journal-title":"Neurosci. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbr.2017.01.004","article-title":"Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects","volume":"321","author":"Palleria","year":"2017","journal-title":"Behav. Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP\/PS1\/Tau Triple Transgenic Mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer\u2019s disease","volume":"15","author":"Manning","year":"2013","journal-title":"Neuromolecular Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chaves Filho, A.M., Cunha, N.L., de Souza, A.G., Verde-Ramo Soares, M., Juc\u00e1, P.M., de Queiroz, T., Souza Oliveira, J.V., Valvassori, S.S., Barichello, T., and Quevedo, J. (2020). The GLP1R agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 99.","DOI":"10.1016\/j.pnpbp.2020.109872"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"114386","DOI":"10.1016\/j.bbr.2023.114386","article-title":"GLP-1 agonist Liraglutide prevents MK-801-induced schizophrenia-like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal cortex in Balb\/c mice","volume":"445","author":"Kutlu","year":"2023","journal-title":"Behav. Brain Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","article-title":"Treating cognitive impairment in schizophrenia with GLP1RA: An overview of their therapeutic potential","volume":"30","author":"Flintoff","year":"2021","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41380-023-02104-0","article-title":"Investigating the shared genetic architecture between schizophrenia and body mass index","volume":"28","author":"Yu","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1176\/appi.ajp.20220660","article-title":"Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors","volume":"180","author":"Rahman","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/pcn.13372","article-title":"Shared genetic components between metabolic syndrome and schizophrenia: Genetic correlation using multipopulation data sets","volume":"76","author":"Aoki","year":"2022","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"118645","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1017\/S0033291716003366","article-title":"The relationship between cognitive impairment in schizophrenia and metabolic syndrome: A systematic review and meta-analysis","volume":"47","author":"Bora","year":"2017","journal-title":"Psychol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15731","DOI":"10.1073\/pnas.1511593112","article-title":"Obesity diminishes synaptic markers, alters microglial morphology, and impairs cognitive function","volume":"112","author":"Bocarsly","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fornari Laurindo, L., Barbalho, S.M., Guiguer, E.L., Soares de Souza, M.S., de Souza, G.A., Fidalgo, T.M., Ara\u00fajo, A.C., de Souza Gonzaga, H.F., de Bortoli Teixeira, D., and de Oliveira Silva Ullmann, T. (2022). GLP-1a: Going beyond Traditional Use. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020739"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1007\/s43440-021-00274-8","article-title":"Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression","volume":"73","author":"Detka","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The Antidepressant Effects of GLP1R Agonists: A Systematic Review and Meta-Analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Li, J.R., Cao, J., Wei, J., and Geng, W. (2023). Case Report: Semaglutide-associated depression: A report of two cases. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1238353"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Selman, A., Dai, J., Driskill, J., Reddy, A.P., and Reddy, P.H. (2025). Depression and obesity: Focus on factors and mechanistic links. Biochim. Biophys. Acta Mol. Basis Dis., 1871.","DOI":"10.1016\/j.bbadis.2024.167561"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: A pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mehy.2017.12.029","article-title":"Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature","volume":"111","author":"McElroy","year":"2018","journal-title":"Med. Hypotheses"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e7325","DOI":"10.1136\/bmj.e7325","article-title":"Use of Mendelian randomisation to assess potential benefit of clinical intervention","volume":"345","author":"Burgess","year":"2012","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"Claringbould","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41588-022-01058-3","article-title":"Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation","volume":"54","author":"Mahajan","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/hmg\/ddy271","article-title":"Meta-analysis of genome-wide association studies for height and body mass index in \u223c700000 individuals of European ancestry","volume":"27","author":"Yengo","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41588-022-01285-8","article-title":"Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains","volume":"55","author":"Demontis","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","article-title":"FinnGen provides genetic insights from a well-phenotyped isolated population","volume":"613","author":"Kurki","year":"2023","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41588-019-0439-2","article-title":"Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa","volume":"51","author":"Watson","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/mp.2016.11","article-title":"Meta-analysis of genome-wide association studies of anxiety disorders","volume":"21","author":"Otowa","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41588-019-0344-8","article-title":"Identification of common genetic risk variants for autism spectrum disorder","volume":"51","author":"Grove","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41588-021-00857-4","article-title":"Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology","volume":"53","author":"Mullins","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","article-title":"Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions","volume":"22","author":"Howard","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1038\/s41467-019-12576-w","article-title":"International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci","volume":"10","author":"Nievergelt","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511, 421\u2013427.","DOI":"10.1038\/nature13595"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S2215-0366(20)30339-4","article-title":"A large-scale genome-wide association study meta-analysis of cannabis use disorder","volume":"7","author":"Johnson","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1176\/appi.ajp.2018.18040369","article-title":"Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts","volume":"176","author":"Palmer","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","unstructured":"Yan, R., Liu, L., Tzoulaki, I., Fan, J., Targher, G., Yuan, Z., and Zhao, J. (2024). Genetic Evidence for GLP-1 and GIP Receptors as Targets for Treatment and Prevention of MASLD\/MASH. Liver Int., in press."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/sim.3034","article-title":"Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","article-title":"Guidelines for performing Mendelian randomization investigations: Update for summer 2023","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet. Epidemiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet. Epidemiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ije\/dyy258","article-title":"Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption","volume":"48","author":"Bowden","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","article-title":"Mendelian randomisation for mediation analysis: Current methods and challenges for implementation","volume":"36","author":"Carter","year":"2021","journal-title":"Eur. J. Epidemiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s00125-017-4396-y","article-title":"The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: A two-step, two-sample Mendelian randomisation study","volume":"60","author":"Xu","year":"2017","journal-title":"Diabetologia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s00125-022-05705-6","article-title":"Mediators of the association between educational attainment and type 2 diabetes mellitus: A two-step multivariable Mendelian randomisation study","volume":"65","author":"Zhang","year":"2022","journal-title":"Diabetologia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/651257","article-title":"Reconsidering Baron and Kenny: Myths and Truths about Mediation Analysis","volume":"37","author":"Zhao","year":"2010","journal-title":"J. Consum. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:56:07Z","timestamp":1760028967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":86,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062741"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062741","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}